Eric K. Singhi, M.D.,and Ben Creelan, M.D., discuss how over the past 5 years, PD-1 inhibitors have reshaped first-line therapy for advanced non-small cell lung cancer (NSCLC), improving survival outcomes. Biomarkers like PD-L1 and patient characteristics guide treatment choices. New data on cemiplimab enhances decision-making, balancing efficacy with quality of life.
EP. 1: Setting the Stage: Immunotherapy’s Impact and EMPOWER-Lung 1 Study Design
March 28th 2025Panelists discuss how over the last five years, immunotherapy, particularly PD-1 inhibitors, has revolutionized advanced non-small cell lung cancer (NSCLC) treatment, offering promising first-line therapy options. Prior to the EMPOWER-Lung 1 study, PD-1 inhibitors showed improved survival outcomes as monotherapy. Treatment considerations have since evolved to incorporate patient-specific factors, optimizing therapy based on individual characteristics.
Watch
EP. 2: Optimizing First-Line and Sequential Therapy in Advanced NSCLC
March 28th 2025Panelists discuss how biomarkers like PD-L1 guide first-line therapy in advanced non-small cell lung cancer (NSCLC), with higher expression favoring PD-1 inhibitors. Other factors like performance status and comorbidities also support their use. Post progression, PD-1 inhibitors are often used alone or in combination for subsequent lines of treatment.
Watch
EP. 3: EMPOWER-Lung 1: Baseline Characteristics and Modern Treatment Considerations in NSCLC
April 4th 2025Panelists discuss how, at their practices, histology, staging and ECOG performance status guide treatment decisions for advanced non-small cell lung cancer (NSCLC). Compared with EMPOWER-Lung 1, these factors remain crucial. Key biomarkers, such as PD-L1 expression, influence PD-1 inhibitor efficacy. In 2025, treatment options are more personalized with emerging therapies.
Watch
EP. 4: Evaluating Five-Year Efficacy Outcomes in EMPOWER-LUNG 1
April 4th 2025Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival (PFS). Cemiplimab’s outcomes align well with other PD-1/PD-L1 inhibitors, influencing clinical decisions for its use as a first-line treatment.
Watch
EP. 5: Subgroup Analyses of EMPOWER-LUNG 1
April 11th 2025Panelists discuss how subgroup analyses of the EMPOWER-Lung 1 study assessed the efficacy of pembrolizumab across various patient groups, including those with different PD-L1 expression levels, tumor histology and prior therapies. Results demonstrated consistent survival benefits, highlighting pembrolizumab’s broad clinical applicability in advanced non-small cell lung cancer (NSCLC).
Watch
EP. 6: Managing Safety and Quality of Life With Cemiplimab in Advanced NSCLC
April 11th 2025Panelists discuss how balancing survival benefits with quality of life involves careful monitoring of treatment-related adverse effects. Managing immune-related adverse events in patients on immune checkpoint inhibitors like cemiplimab requires early detection, timely intervention and proactive strategies to minimize impact on outcomes.
Watch
EP. 7: The Role of Continuing Cemiplimab in Second-Line Therapy After Progression
April 18th 2025Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.
Watch
EP. 8: Closing Insights: The Future of Cemiplimab in NSCLC and Beyond
April 18th 2025Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.
Watch